Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy

Annals of Hematology

Volumn 72, Issue 1, 1996, Pages 1-9

  Bokemeyer, C ^a   Kuczyk, M A ^b   Kohne H ^c   Einsele, H ^a   Kynast, B ^b   Schmoll, H J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Section of Pathology   (Germany)

Author keywords

Dose intensive chemotherapy; G CSF; Germ cell tumors; GM CSF; Hematopoietic growth factors; Human testicular cancer cell lines; Infection; Neutropenia; Peripheral blood stem cells (PBSC); Stem cell factor (SCF); Testicular cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE;

BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; GERM CELL TUMOR; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; METASTASIS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; SEPSIS; TESTIS CANCER; THROMBOCYTOPENIA;

EID: 0030050024     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00663009     Document Type: Review

References (62)

1. Amman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598
2. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ (1995) Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamidc-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin Oncol 13:79-86
3. Beyer J, Schwella N, Strohscheer I, Schwander I, Zingsem J, Sefke S, Huhn D, Siegert W (1994) Randomized comparison of bematopoietic rescue with stem/progenitor cells from bone marrow or peripheral blood after high-dose chemotherapy in germ cell tumors. Bone Marrow Transplant 14 [Suppl 1]: 45
4. Birch R, Williams S, Cone A, Einhorn LH, Roark P, Turner S. Greco FA (1986) Prognostic factors for favourable outcome in disseminated germ cell tumours. J Clin Oncol 4:400-407
5. Blanke C, Loehrer PJ, Einhorn LH, Nichols C (1994) A phase-II study of VP-16 plus ifosfamide plus cisplatin plus vinblastine plus, bleomycin (VIP/VB) with filgrastim for advanced stage testicular cancer. Proc Am Soc Clin Oncol 13:234
6. Bokemeyer C, Schmoll HJ, Casper J, Kuczyk M, Poliwoda H (1993) No growth stimulation of heterotransplanted human testicular cancer cell lines by recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Int J Oncol 3:77-80
7. Bokemeyer C, Schmoll HJ, Harstrick A (1993) Side effects of GM-CSF in advanced testicular cancer. Eur J Cancer 29A: 924 (letter)
8. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Räth U, Hohnloser J, Clemm C, Berdel W, Siegert W, Rüther U, Ostermann H, Kneba M, Hartlapp JH, Schröder M, Poliwoda H (1993) A phase-I/II study of a stepwise dose-escalated regimen of cisplatin. etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GMCSF) in patients with advanced germ cell tumours. Eur J Cancer 29A: 2225-2231
9. Bokemeyer C, Beyer J, Schmoll HJ (1994) The role of dose-intensified chemotherapy for the treatment of metastatic germ cell tumours. Forum 4:671-680
10. Bokemeyer C, Schmoll HJ, Arseniev L, Metzner B, Rüther U, Illiger HJ, Link H, Poliwoda H (1994) Treatment of advanced testicular cancer with dose intensified chemotherapy plus GM-CSF alone or G-CSF and sequential harvesting and reinfusion of peripheral blood stem cells (PBSC). Proc Am Soc Clin Oncol 13:236
11. Bokemeyer C, Harstrick A, Rüther U, Metzner B, Arseniev L. Kadar J, Illiger HJ, Link H, Raichele A, Beyer J, Hossfeld DK, Schmoll HJ (1995) Sequential treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell (PBSC) support in advanced germ cell cancer, Proc Am Soc Clin Oncol 14:596
12. Boogaerts MA (1994) Growth factors in hematology: prophylactic versus interventional use Eur J Cancer 30A: 238-243
13. Bosl GJ, Geller N, Cirrincone C, Vogelzang NJ, Kennedy BJ, Whitmore WF, Vugrin D, Scher H, Nisselbaum J, Golbey RB (1983) Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407
14. Brugger W, Bross K, Frisch J, Lindemann A, Kanz L, Merteismann R (1992) Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin, Blood 79:1193-1200
15. Buzello H (1995) Effect of granulocyte colony stimulating factor (G-CSF) on growth of testicular cancer cells in vitro. In: Schnorr D. Loenig SA, Weißbach L (eds) Hodentumoren - testis cancer. Blackwell Wissenschaftsverlag, Berlin, pp 197-198
16. Cimoli G, Russo P, Billi G, Nariani GL, Rovini E, Venturini M (1991) Human granulocyte-macrophage colony-stimulating factor, a growth factor active on human ovarian cancer cells. Jpn J Cancer Res 82:1196-1198
17. Daugaard G, Roerth M (1992) Treatment of poor-risk germ-cell tumors with high-dose cisplatin and etoposide combined with bleomycin. Ann Oncol 3:277-282
18. Diaz-Rubio E, Adrover E (1994) Use of granulocyte growth factors in solid tumours. Eur J Cancer 30A: 120-122
19. Dunn T, Bokemeyer C, Hanmann K, Rie C, Schmoll HJ (1994) Effect of hematopoietic growth factors (HGFs) on the growth of human embryonic carcinoma cell lines in reduced or serum free culture. Ann Oncol 5 [Suppl 8]: 38
20. Einhorn LH (1990) Treatment of testicular cancer: a new improved model. J Clin Oncol 11:1777-1781
21. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, Greco FA (1989) Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group Protocol. J Clin Oncol 7:387-391
22. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Amman KH (1990) High-dose ifosfamide with mesna uroprotection. J Clin Oncol 8:170-178
23. Fossa S, Kaye SB, Cullen M, De Wit R, Bodrogi I, van Groeningen C, Sylvester R, Stenning S, Kaye SB, Cullen M, De Wit R, Lallemand E, Mead GM (1995) An MRC/EORTC randomized trial in poor-prognosis metastatic teratoma, comparing treatment with/without filgrastim. Proc Am Soc Clin Oncol 14:656
24. Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Bergamnn L. Lammers U, Hohnloser J, Dölken G, Reichhardt P, Siegert W, Natt F, Räth U, Wilke H, Poliwoda H (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol 2:197-202
25. Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, Bergmann L, Lammers U, Freund M, Poliwoda H (1991) Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsed germ cell carcinoma. J Clin Oncol 9:1549-1555
26. Husband DJ, Green JA (1992) POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer 28A: 86-91
27. Jost LM, Pichert G, Stahel RA (1990) Placebo controlled phase-I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy. Ann Oncol 1:439-442
28. Kanz L, Lindemann A, Oster W, Herrmann F, Mertelsmann R (1991) Hemopoietins in clinical oncology. J Clin Oncol 14 [Suppl I]: 27-33
29. Levi JA, Toner G (1993) Dose intensive chemotherapy for poor prognosis germ cell malignancies. International Germ Cell Tumour Conference. Leeds, England
30. Lewis CR, Fossa SD, Mead G, Ten Bokkel Huinik W, Harding MJ, Mill L, Paul J, Jones WG, Rodenburg CJ, Cantwell B (1991) BOP/VIP - a new platinum-intensive chemotherapy regimen for poor prognosis serm cell tumours. Ann Oncol 2:203-211
31. Lieschke GJ, Burgess AW (1992) Granulocyte-colony-stimulating factor and granulocyte-macrophase colony-stimulating factor. N Engl J Med 327:28-35
32. Linkesch W, Krainer M, Wagner A (1992) Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors (NSGCT). Proc Am Soc Clin Oncol 11:196
33. Loehrer PJ, Einhorn LH, Williams SD (1986) VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 4:528-536
34. Loehrer PJ, Einhorn LH, Elson P, Williams SD, Havlin K, Vogelzang NJ, Crawford ED, Trump DL (1993) Phase-III study of cispaatin plus etoposide (VP16) with either bleomycin (B) or ifosfamide (1) in advanced-stage germ cell tumours (GCT): an Intergroup trial. Proc Am Soc Clin Oncol 12:831
35. Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE (1985) Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. J Clin Oncol 3:326-335
36. Lynch J, Lee R, Gross M, Velus K, Hutchenson C, Ayash L, Weiner R, Moreb J (1994) Time to myeloid recovery is related to number of peripheral blood (PB) progenitors infused after hish-dose chemotherapy. Proc Am Soc Clin Oncol 13:97
37. Mandanas RA, Broun ER, Nichols CR, Salzman D, Turns M, Einhorn LH (1993) Phase-I/II dose-escalation study of carboplatin (CBDCA) and etoposide (VP-16) with autologous marrow support done in tandem for refractory serm cell tumors (GCT). Proc Am Soc Clin Oncol 12:240
38. Medical Research Council Working Party on Testicular Tumours (1985) Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicenter study. Lancet 1:8-11
39. Miyagawa K, Chiba S, Shibuya K, Piao YF, Matsuki S, Yokota J, Terada M, Miyazono K, Takaku F (1990) Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on nonhematopoietic tumour cell lines. J Cell Physiol 143:483-487
40. Motzer RJ, Bosl GJ (1992) High-dose chemotherapy for resistant serm cell tumors: recent advances and future directions. J Natl Cancer Inst 84:1703-1709
41. Molzer RJ, Geller NL, Bosl GJ (1990) The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer 66:857-861
42. Motzer RJ, Bajorin DF, Bosl GJ (1992) "Poor risk" germ cell tumours: current progress and future directions. Semin Oncol 19:206-214
43. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550-556
44. Motzer RJ, Gulali SC, Mazumdar M, Bajorin DF, Vlamis V, Lyn P, Bosl GJ (1993) Phase-II trial of VAB-6+ high-dose carboplatin + etoposide (HD C+ E) with autologous bone marrow transplantation (AUBMT) for poor-risk germ cell tumor (GCT) patients (PTS). Proc Am Soc Clin Oncol 12:233
45. Motzer RJ, Mazumdar M, Subhash CG, Bajorin DF, Lyn P, Vlamis V, Bosl GJ (1993) Phase-II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835
46. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Currie V, Bosl GJ (1993) An analysis of the effect of dose intensity on response, event-free survival and overall survival in patients with germ cell tumours (GCT) receiving ifosfamide-based salvage therapy. Proc Am Soc Clin Oncol 12:721
47. Nakagawa S, Sugimoto K, Mikamie K, Watanabe H, Sonoda Y, Kuzuyama Y, Abe T, Fuji H (1994) Successful collection of peripheral blood stem cells mobilized by high-dose etoposide for patients with chemotherapy-resistant and/or poor prognostic testicular cancer. Nippon Hinyokika Gakkai Zasshi 85:571-578
48. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ cell tumours. N Engl J Med 322:1425-1429
49. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor risk germ cell tumours: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172
50. Roach S, Cooper S, Bennet W, Pera MF (1993) Cultured cell lines from human teratomas: windows into tumor growth and differentiation and early human development. Eur Urol 23:82-88
51. Rodenhuis S, Baars JW, Schornagel JH, Vlasveld LT, Mandjes I, Pinedo HM, Richel DJ (1992) Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplaniation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 3:855-860
52. Rodenhuis S, van der Wall E, Schornagel JH, Holtkamp M, Nooijen WJ, Baars JW (1994) Development of a multiple high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa and carboplatin with peripheral stem cell transplantation (PSCT). Proc Am Soc Clin Oncol 13:248
53. Schmoll HJ, Schubert I, Arnold H, Dölken G, Hecht T. Bergmann L. Illiger J, Fink U, Preiss J, Pfreundschuh M, Kaulen H, Bonfert B, Ho AD, Manegold C, Mayr A, Hoffmann L, Weiss J, Hecker H (1987) Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin. Int J Androl 10:311-317
54. Sehrt J, Pietsch T, Schöffski P, Bokemeyer C, Kuczyk MA, Schmoll HJ, Jonas U (1994)A possible role for stem cell factor (SCF) and its receptor C-kit in malignant germ cell tumors. Proc Am Assoc Cancer Res 35:255
55. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D (1994) High-dose treatment with carboplatin. etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory serm cell cancer: a phase-I/II study. J Clin Oncol 12:1223-1231
56. Sobrevilla-Calvo P, Zinser JW, Lara FU, Acosta-Barreda A, Guarner-Lans J, Miranda-Lopez E, Reynoso-Gomez E (1994) High-dose ICE (ifosfamide (I), carboplatin (C) and etoposide (E)) regimen supported with autologous transplantation of refrigerated peripheral blood stem cells (PAPBSC), mobilized with G-CSF: description of a standard method to give high-dose chemotherapy (CT). Proc Am Soc Clin Oncol 13:465
57. Spitzer G, Adkins DR, Spencer V, Dunphy FR, Petruska PJ, Velasquez WS, Bowers CE, Kronmueller N, Niemeyer R, McIntyre W (1994) Randomized study of growth factors postperipheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661-670
58. Stoter G, Sleijfer DT, Schornagel JH, ten Bokkel-Huinink WW, Vermeijlen K, Sylvester R on behalf of the EORTC Genito-Urinary Group (1993) BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular caner (NSTC). Proc Am Soc Clin Oncol 12:232
59. Tjulandin S, Garin A, Stenina M, Mesherjakov N, Sidorova A, Sokolov N, Ljubimova N, Gutierrez F, Kupchan D, Graubner M (1993) Carboplatin (CBDA), etoposide (VP-16). bleomycin (B) and GM-CSF in patients (pts) with poor risk nonseminomatous germ cell tumours (NSGCT). Proc Am Soc Clin Oncol 12:245
60. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987)Treatment of disseminated germ-cell tumors with cisplatin. bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435-1440
61. Wolff SN, Johnson DH, Hainsworth JD, Greco FA (1984) High-dose VP-16-213 monotherapy for refractory germinal malignancies. A phase-II study. J Clin Oncol 4:271-274
62. Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman SJ, Stephens RL, Natale RB, Bouroncle BA, Blumenstein BA, Cummings GD (1991) A randomized trial of cisplatin, vinblastine and bleomycin versus vinblastine. cisplatin and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group Study. J Clin Oncol 9:70-76